<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04131192</url>
  </required_header>
  <id_info>
    <org_study_id>PCD-DZ650-19-001</org_study_id>
    <nct_id>NCT04131192</nct_id>
  </id_info>
  <brief_title>Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer</brief_title>
  <official_title>A Phase Ib, Multi-center, Open-label Study of Z650 and Gemcitabine in Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase IB trial is studying how well giving gemcitabine together with Z650 works in
      treating patients with metastatic or recurrent pancreatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase IB trial is studying how well giving gemcitabine together with Z650 works in
      treating patients with metastatic or recurrent pancreatic cancer.This phase IB trial is
      Multi-center and open。
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2019</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of dose limiting toxicities of each subject</measure>
    <time_frame>21 days</time_frame>
    <description>Rate will be assessed through summaries of adverse events, clinical laboratory abnormalities, and changes in physical exam and vital signs. All subjects who receive a single dose of study medication will be considered evaluable for safety.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events related to pulse dose Z650 and gemcitabine</measure>
    <time_frame>up to 4 weeks after last dose</time_frame>
    <description>description, timing, grade (Common Terminology Criteria for Adverse Events Version 5.0 [CTCAE v5.0]), severity, seriousness, and relatedness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>up to approximately 24 months</time_frame>
    <description>Overall response rate (ORR), defined as a partial response (PR) or complete response (CR) occurring at any point post-treatment according to Response Evaluation Criteria in Solid Tumors as assessed by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>up to approximately 24 months</time_frame>
    <description>DCR, proportion of patients with best overall response of CR, PR or stable disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to approximately 24 months</time_frame>
    <description>DOR, defined as time from the first documented CR or PR to first documented progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>up to approximately 24 months</time_frame>
    <description>PFS, defined as time from date of treatment to disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to approximately 24 months</time_frame>
    <description>OS, defined as time from date of treatment to death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>z650 and Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Z650:250 or 300 or 200 mg/d, starting on the 2nd day, once a day, continuous administration, or about half an hour after a meal Gemcitabine: intravenously at 1000 mg/m2 on Days 1, 8, of a 21-day cycle FOR the 4-6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Z650</intervention_name>
    <description>250 or 300 or 200 mg/d, starting on the 2nd day, once a day, continuous administration, or about half an hour after a meal</description>
    <arm_group_label>z650 and Gemcitabine</arm_group_label>
    <other_name>larotinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, of a 21-day cycle ，for 4-6 cycles</description>
    <arm_group_label>z650 and Gemcitabine</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        18 ≤ age ≤ 75 years old, male or female is not limited; Eastern Cooperative Oncology Group
        (ECOG) performance status (PS) 0 or 1 Life expectancy of ≥ 12 weeks Pathologically
        confirmed advanced pancreatic cancer defined as non-operable in a curative intent, locally
        recurrent, or metastatic disease.

        Exclusion Criteria:

        adjuvant treatment with gemcitabine within 6 months prior to the first dose; Radiotherapy
        and anti-cancer Chinese patent medicine treatment were performed within 4 weeks before the
        first dose; Gastrointestinal diseases that could affect the absorption of Z650, (e.g.,
        serious swallowing obstruction, chronic diarrhea, bowel obstruction); Doppler ultrasound
        evaluation of Left ventricular ejection fraction &lt; 50%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>shu zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>lianke liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yingjun zhang</last_name>
    <phone>0769-85315888-2180</phone>
    <email>ZhangYingjun@hec.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>China/jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lianke liu</last_name>
      <phone>13951623290</phone>
      <email>liulianke@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>lianke liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>shandong Cancer Hospital</name>
      <address>
        <city>Jinan</city>
        <state>China/shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhang shu</last_name>
      <phone>15553126791</phone>
      <email>szhang@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>zhang shu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 10, 2019</study_first_submitted>
  <study_first_submitted_qc>October 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2019</study_first_posted>
  <last_update_submitted>February 9, 2020</last_update_submitted>
  <last_update_submitted_qc>February 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

